Logo image of ASND

ASCENDIS PHARMA A/S - ADR (ASND) Stock Fundamental Analysis

NASDAQ:ASND - Nasdaq - US04351P1012 - ADR - Currency: USD

177.71  +6.91 (+4.05%)

After market: 177.71 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ASND. ASND was compared to 557 industry peers in the Biotechnology industry. ASND has a bad profitability rating. Also its financial health evaluation is rather negative. ASND is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ASND has reported negative net income.
ASND had a negative operating cash flow in the past year.
ASND had negative earnings in each of the past 5 years.
ASND had a negative operating cash flow in each of the past 5 years.
ASND Yearly Net Income VS EBIT VS OCF VS FCFASND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

ASND's Return On Assets of -32.19% is fine compared to the rest of the industry. ASND outperforms 64.09% of its industry peers.
Industry RankSector Rank
ROA -32.19%
ROE N/A
ROIC N/A
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASND Yearly ROA, ROE, ROICASND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

ASND has a better Gross Margin (85.30%) than 88.51% of its industry peers.
ASND's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ASND so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
ASND Yearly Profit, Operating, Gross MarginsASND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
ASND has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ASND has been increased compared to 5 years ago.
The debt/assets ratio for ASND has been reduced compared to a year ago.
ASND Yearly Shares OutstandingASND Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ASND Yearly Total Debt VS Total AssetsASND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.32, we must say that ASND is in the distress zone and has some risk of bankruptcy.
ASND's Altman-Z score of 0.32 is fine compared to the rest of the industry. ASND outperforms 63.73% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.32
ROIC/WACCN/A
WACC6.74%
ASND Yearly LT Debt VS Equity VS FCFASND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

A Current Ratio of 1.04 indicates that ASND should not have too much problems paying its short term obligations.
ASND's Current ratio of 1.04 is on the low side compared to the rest of the industry. ASND is outperformed by 87.43% of its industry peers.
A Quick Ratio of 0.71 indicates that ASND may have some problems paying its short term obligations.
ASND's Quick ratio of 0.71 is on the low side compared to the rest of the industry. ASND is outperformed by 90.48% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.71
ASND Yearly Current Assets VS Current LiabilitesASND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

ASND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.12%, which is quite impressive.
The Revenue has grown by 12.06% in the past year. This is quite good.
ASND shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 93.57% yearly.
EPS 1Y (TTM)34.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.3%
Revenue 1Y (TTM)12.06%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%5.28%

3.2 Future

ASND is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.02% yearly.
Based on estimates for the next years, ASND will show a very strong growth in Revenue. The Revenue will grow by 55.15% on average per year.
EPS Next Y39.83%
EPS Next 2Y48.04%
EPS Next 3Y45.83%
EPS Next 5Y39.02%
Revenue Next Year102.22%
Revenue Next 2Y89.42%
Revenue Next 3Y76.58%
Revenue Next 5Y55.15%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ASND Yearly Revenue VS EstimatesASND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
ASND Yearly EPS VS EstimatesASND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20 30

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASND. In the last year negative earnings were reported.
ASND is valuated quite expensively with a Price/Forward Earnings ratio of 121.98.
88.51% of the companies in the same industry are more expensive than ASND, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.41, ASND is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 121.98
ASND Price Earnings VS Forward Price EarningsASND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASND Per share dataASND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ASND's earnings are expected to grow with 45.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.04%
EPS Next 3Y45.83%

More info and screens

0

5. Dividend

5.1 Amount

ASND does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASCENDIS PHARMA A/S - ADR

NASDAQ:ASND (6/16/2025, 8:00:01 PM)

After market: 177.71 0 (0%)

177.71

+6.91 (+4.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)09-01 2025-09-01/amc
Inst Owners112.89%
Inst Owner Change2.68%
Ins Owners0.78%
Ins Owner ChangeN/A
Market Cap10.75B
Analysts87.83
Price Target226.12 (27.24%)
Short Float %5.64%
Short Ratio6.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.39%
Min EPS beat(2)-3.72%
Max EPS beat(2)34.5%
EPS beat(4)2
Avg EPS beat(4)-0.39%
Min EPS beat(4)-35.43%
Max EPS beat(4)34.5%
EPS beat(8)4
Avg EPS beat(8)-3.32%
EPS beat(12)6
Avg EPS beat(12)-2.3%
EPS beat(16)8
Avg EPS beat(16)0.8%
Revenue beat(2)2
Avg Revenue beat(2)23.51%
Min Revenue beat(2)4.58%
Max Revenue beat(2)42.44%
Revenue beat(4)2
Avg Revenue beat(4)-10.53%
Min Revenue beat(4)-57.97%
Max Revenue beat(4)42.44%
Revenue beat(8)5
Avg Revenue beat(8)14.04%
Revenue beat(12)9
Avg Revenue beat(12)20.93%
Revenue beat(16)12
Avg Revenue beat(16)24.32%
PT rev (1m)0%
PT rev (3m)6.75%
EPS NQ rev (1m)-4.1%
EPS NQ rev (3m)-13.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.33%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)11.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 121.98
P/S 25.19
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.77
EYN/A
EPS(NY)1.46
Fwd EY0.82%
FCF(TTM)-4.23
FCFYN/A
OCF(TTM)-4.19
OCFYN/A
SpS7.05
BVpS-3.63
TBVpS-3.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.3%
FCFM N/A
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
F-Score3
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.86%
Cap/Sales 0.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 0.71
Altman-Z 0.32
F-Score3
WACC6.74%
ROIC/WACCN/A
Cap/Depr(3y)33.9%
Cap/Depr(5y)97.41%
Cap/Sales(3y)9.88%
Cap/Sales(5y)130.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.3%
EPS Next Y39.83%
EPS Next 2Y48.04%
EPS Next 3Y45.83%
EPS Next 5Y39.02%
Revenue 1Y (TTM)12.06%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%5.28%
Revenue Next Year102.22%
Revenue Next 2Y89.42%
Revenue Next 3Y76.58%
Revenue Next 5Y55.15%
EBIT growth 1Y9.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.65%
EBIT Next 3Y56.61%
EBIT Next 5YN/A
FCF growth 1Y57.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.24%
OCF growth 3YN/A
OCF growth 5YN/A